MicroRNA‑138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9

Hu,Bo; Wang,Jianbo; Jin,Xunbo

doi:10.3892/ol.2017.7160

MicroRNA‑138 suppresses cell proliferation and invasion of renal cell carcinoma by directly targeting SOX9

Authors:
- Bo Hu
- Jianbo Wang
- Xunbo Jin
View Affiliations

Affiliations: Minimally Invasive Urology Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250012, P.R. China, Oncology Center, Qilu Hospital of Shandong University, Jinan, Shandong 250000, P.R. China
Published online on: October 10, 2017 https://doi.org/10.3892/ol.2017.7160
Pages: 7583-7588

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An accumulating number of studies have reported that the expression levels of microRNAs (miRNAs/miRs) are dysregulated in a variety of human cancer types, including renal cell carcinoma (RCC). miRNAs play essential functions in tumorigenesis and the progression of tumors by serving as oncogenes or tumor suppressors. Recently, the expression and functions of miR‑138 have been studied in a number of human cancer types; however, its role in RCC remains poorly understood. In the present study, the results revealed that miR‑138 was significantly downregulated in RCC cell lines and tissues, and that low expression levels of miR‑138 were correlated with histological grade, tumor stage and lymph node metastasis. In functional studies, restoration of miR‑138 expression inhibited cell proliferation and invasion of ACHN and A498 cells. In addition, SOX9 was validated as a direct target gene of miR‑138 in RCC. SOX9 knockdown inhibited cell proliferation and invasion of RCC, with a similar effect to that induced by miR‑138, rendering SOX9 a functional target of miR‑138 in the disease. These findings indicate that miR‑138 may present a novel target for therapeutic strategies in RCC.

View Figures

View References

1	Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
2	Peng J, Mo R, Ma J and Fan J: let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma. World J Surg Oncol. 13:1752015. View Article : Google Scholar : PubMed/NCBI
3	Nerich V, Hugues M, Paillard MJ, Borowski L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T, Mouillet G, et al: Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. Onco Targets Ther. 7:365–374. 2014. View Article : Google Scholar : PubMed/NCBI
4	Wang L, Williamson SR, Wang M, Davidson DD, Zhang S, Baldridge LA, Du X and Cheng L: Molecular subtyping of metastatic renal cell carcinoma: Implications for targeted therapy. Mol Cancer. 13:392014. View Article : Google Scholar : PubMed/NCBI
5	Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, Evans A and Yousef GM: Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol. 59:721–730. 2011. View Article : Google Scholar : PubMed/NCBI
6	Motzer RJ and Russo P: Systemic therapy for renal cell carcinoma. J Urol. 163:408–417. 2000. View Article : Google Scholar : PubMed/NCBI
7	Kurozumi A, Kato M, Goto Y, Matsushita R, Nishikawa R, Okato A, Fukumoto I, Ichikawa T and Seki N: Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma. Int J Oncol. 48:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
8	Coppin C, Kollmannsberger C, Le L, Porzsolt F and Wilt TJ: Targeted therapy for advanced renal cell cancer (RCC): A cochrane systematic review of published randomised trials. BJU Int. 108:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zeng Y: Principles of micro-RNA production and maturation. Oncogene. 25:6156–6162. 2006. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Carrington JC and Ambros V: Role of microRNAs in plant and animal development. Science. 301:336–338. 2003. View Article : Google Scholar : PubMed/NCBI
12	Engels BM and Hutvagner G: Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene. 25:6163–6169. 2006. View Article : Google Scholar : PubMed/NCBI
13	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
14	Giannakakis A, Coukos G, Hatzigeorgiou A, Sandaltzopoulos R and Zhang L: miRNA genetic alterations in human cancers. Expert Opin Biol Ther. 7:1375–1386. 2007. View Article : Google Scholar : PubMed/NCBI
15	Nelson KM and Weiss GJ: MicroRNAs and cancer: Past, present and potential future. Mol Cancer Ther. 7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
16	Goto Y, Kurozumi A, Enokida H, Ichikawa T and Seki N: Functional significance of aberrantly expressed microRNAs in prostate cancer. Int J Urol. 22:242–252. 2015. View Article : Google Scholar : PubMed/NCBI
17	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
18	Dias F, Teixeira AL, Santos JI, Gomes M, Nogueira A, Assis J and Medeiros R: Renal cell carcinoma development and miRNAs: A possible link to the EGFR pathway. Pharmacogenomics. 14:1793–1803. 2013. View Article : Google Scholar : PubMed/NCBI
19	Li Z, Yu X, Shen J and Jiang Y: MicroRNA dysregulation in uveal melanoma: A new player enters the game. Oncotarget. 6:4562–4568. 2015. View Article : Google Scholar : PubMed/NCBI
20	Lv C, Bai Z, Liu Z, Luo P and Zhang J: MicroRNA-495 suppresses human renal cell carcinoma malignancy by targeting SATB1. Am J Transl Res. 7:1992–1999. 2015.PubMed/NCBI
21	Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu Y, Li J, Zhang Q, Li Q and Li L: MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. Biomed Pharmacother. 77:135–141. 2016. View Article : Google Scholar : PubMed/NCBI
22	Sun DK, Wang JM, Zhang P and Wang YQ: MicroRNA-138 regulates metastatic potential of bladder cancer through ZEB2. Cell Physiol Biochem. 37:2366–2374. 2015. View Article : Google Scholar : PubMed/NCBI
23	Gao S, Wang J, Xie J, Zhang T and Dong P: Role of miR-138 in the regulation of larynx carcinoma cell metastases. Tumour Biol. Oct 24–2015.(Epub ahead of print).
24	Cristobal I, Torrejon B, González-Alonso P, Manso R, Rojo F and García-Foncillas J: Downregulation of miR-138 as a contributing mechanism to Lcn-2 overexpression in colorectal cancer with liver metastasis. World J Surg. 40:1021–1022. 2016. View Article : Google Scholar : PubMed/NCBI
25	Long L, Huang G, Zhu H, Guo Y, Liu Y and Huo J: Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2. J Transl Med. 11:2752013. View Article : Google Scholar : PubMed/NCBI
26	Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, Wang H, Wang S, Su J, Lv X, et al: MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem. 31:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
27	Han L, Zhang G, Zhang N, Li H, Liu Y, Fu A and Zheng Y: Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. Med Oncol. 31:1292014. View Article : Google Scholar : PubMed/NCBI
28	Xu R, Zeng G, Gao J, Ren Y, Zhang Z, Zhang Q, Zhao J, Tao H and Li D: miR-138 suppresses the proliferation of oral squamous cell carcinoma cells by targeting Yes-associated protein 1. Oncol Rep. 34:2171–2178. 2015. View Article : Google Scholar : PubMed/NCBI
29	Ma F, Zhang M, Gong W, Weng M and Quan Z: MiR-138 suppresses cell proliferation by targeting bag-1 in gallbladder carcinoma. PLoS One. 10:e01264992015. View Article : Google Scholar : PubMed/NCBI
30	Yu C, Wang M, Li Z, Xiao J, Peng F, Guo X, Deng Y, Jiang J and Sun C: MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Cell Oncol (Dordr). 38:173–181. 2015. View Article : Google Scholar : PubMed/NCBI
31	Huang B, Li H, Huang L, Luo C and Zhang Y: Clinical significance of microRNA 138 and cyclin D3 in hepatocellular carcinoma. J Surg Res. 193:718–723. 2015. View Article : Google Scholar : PubMed/NCBI
32	Qiu S, Huang D, Yin D, Li F, Li X, Kung HF and Peng Y: Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim Biophys Acta. 1832:1697–1707. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ye XW, Yu H, Jin YK, Jing XT, Xu M, Wan ZF and Zhang XY: miR-138 inhibits proliferation by targeting 3-phosphoinositide-dependent protein kinase-1 in non-small cell lung cancer cells. Clin Respir J. 9:27–33. 2015. View Article : Google Scholar : PubMed/NCBI
34	Han LP, Fu T, Lin Y, Miao JL and Jiang QF: MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3. Tumour Biol. 37:291–298. 2015. View Article : Google Scholar : PubMed/NCBI
35	Li J, Wang Q, Wen R, Liang J, Zhong X, Yang W, Su D and Tang J: miR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med. 19:2793–2805. 2015. View Article : Google Scholar : PubMed/NCBI
36	Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT: MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012. View Article : Google Scholar : PubMed/NCBI